ATE224184T1 - Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe - Google Patents
Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffeInfo
- Publication number
- ATE224184T1 ATE224184T1 AT94930794T AT94930794T ATE224184T1 AT E224184 T1 ATE224184 T1 AT E224184T1 AT 94930794 T AT94930794 T AT 94930794T AT 94930794 T AT94930794 T AT 94930794T AT E224184 T1 ATE224184 T1 AT E224184T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccines
- compositions
- antigens
- microspheres
- microencapsulating antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14179693A | 1993-10-22 | 1993-10-22 | |
| US14355593A | 1993-10-25 | 1993-10-25 | |
| PCT/US1994/011753 WO1995011010A1 (en) | 1993-10-22 | 1994-10-13 | Methods and compositions for microencapsulation of antigens for use as vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE224184T1 true ATE224184T1 (de) | 2002-10-15 |
Family
ID=26839455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94930794T ATE224184T1 (de) | 1993-10-22 | 1994-10-13 | Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0724432B1 (de) |
| JP (1) | JPH09504027A (de) |
| AT (1) | ATE224184T1 (de) |
| AU (1) | AU7980794A (de) |
| CA (1) | CA2172509C (de) |
| DE (1) | DE69431404T2 (de) |
| DK (1) | DK0724432T3 (de) |
| ES (1) | ES2184769T3 (de) |
| WO (1) | WO1995011010A1 (de) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE40786E1 (en) * | 1984-03-16 | 2009-06-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US6514533B1 (en) | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
| ATE197550T1 (de) * | 1993-02-23 | 2000-12-15 | Genentech Inc | Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff |
| DE69415684T2 (de) * | 1993-10-22 | 1999-06-10 | Genentech Inc., San Francisco, Calif. | Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe |
| GB2317340B (en) * | 1995-07-13 | 1998-12-23 | Danbiosyst Uk | Polymeric lamellar substrate particles for drug delivery |
| GB9514285D0 (en) * | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
| US5916597A (en) * | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| GB9709900D0 (en) * | 1997-05-15 | 1997-07-09 | Microbiological Res Authority | Microencapsulated DNA for vaccination and gene therapy |
| EP1579851A3 (de) * | 1997-08-29 | 2009-09-02 | Corixa Corporation | Schnellfreisetzende enkapsulierte bioaktive Wirkstoffe zur Induzierung oder Erhöhung einer immunantwort und Verwendung derselben |
| EP1009386B1 (de) * | 1997-08-29 | 2005-08-31 | Corixa Corporation | Schnellfreisetzende enkapsulierte bioaktive wirkstoffe zur induzierung einer immunantwort und verwendung derselben |
| EP1042001B1 (de) * | 1997-12-16 | 2002-04-03 | Chiron Corporation | Verwendung von mikropartikeln mit submikron öl/wasser emulsionen |
| US7393630B2 (en) | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
| SE9801288D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
| US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
| JP2003522151A (ja) * | 2000-02-08 | 2003-07-22 | インスティテュート・オブ・モレキュラー・アグロバイオロジー | 腸炎菌を包含するバイオ分解性およびバイオ和合性の重合性ミクロスフェア |
| ES2160089B1 (es) * | 2000-03-15 | 2002-05-16 | Inst Cientifico Tecnol Navarra | Procedimiento y aparato para la produccion de microparticulas para la liberacion controlada de farmacos hidrosolubles y vectores virales. aplicacion a la adiministracion de adn plasmidico y de adenovirus recombinantes defectivos. |
| US6565888B1 (en) | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
| WO2003005952A2 (en) * | 2001-07-10 | 2003-01-23 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| WO2004037234A2 (en) | 2002-10-24 | 2004-05-06 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| MXPA05012493A (es) | 2003-05-27 | 2006-05-25 | Forest Laboratories | Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo. |
| US20050260217A1 (en) * | 2004-03-04 | 2005-11-24 | Corixa Corporation | Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof |
| CN100342916C (zh) * | 2004-12-08 | 2007-10-17 | 上海第二医科大学附属第九人民医院 | 一种可生物降解医用材料标记物及其制备 |
| CN101437539B (zh) | 2005-07-05 | 2013-10-02 | 康奈尔研究基金会（有限公司） | 通过干扰cd99l2阻断白细胞迁出和炎症 |
| CN101247826A (zh) | 2005-08-25 | 2008-08-20 | 大鹏药品工业株式会社 | 固定或内包t细胞识别抗原表位肽的生物降解性纳米粒子 |
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| EP2548552B1 (de) | 2007-09-12 | 2015-11-18 | Merz Pharma GmbH & Co. KGaA | Titrationspaket für 1-Amino-Alkylcyclohexane |
| ES2358703B1 (es) * | 2007-11-14 | 2012-03-21 | Universidad Del Pais Vasco | Empleo de micropart�?culas para su uso como vacunas y la liberación de moléculas biológicamente activas. |
| ES2327375B1 (es) | 2007-11-14 | 2010-08-05 | Universidad Del Pais Vasco | Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas. |
| EP2085120A1 (de) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Verwendung von Substanzen zur Behandlung zentraler und peripherer Insulinrezeptorbeeinträchtigung oder Insulinresistenz |
| US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
| TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類 |
| EP2373304B1 (de) | 2008-12-19 | 2014-07-30 | Merz Pharma GmbH & Co. KGaA | Neramexane zur Behandlung von Mastzellen-vermittelten Erkrankungen |
| US20120190690A1 (en) | 2009-06-30 | 2012-07-26 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of weight disorders |
| WO2011000565A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of anxiety |
| WO2011000562A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of certain movement disorders |
| WO2011000564A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of drug addiction |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| US20110294890A1 (en) | 2010-05-28 | 2011-12-01 | Merz Pharma Gmbh & Co. Kgaa | Neramexane for the treatment or prevention of inner ear disorders |
| WO2012023033A2 (en) | 2010-08-18 | 2012-02-23 | Purdue Pharma L.P. | Improved peptide immunogens |
| JP6084931B2 (ja) | 2011-01-20 | 2017-02-22 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン |
| WO2012171653A1 (en) | 2011-06-15 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Sarizotan for use in the treatment of attention deficit hyperactivity disorder (adhd) |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| TW201412325A (zh) | 2012-06-20 | 2014-04-01 | 梅茲製藥有限兩合公司 | 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療 |
| CA2880701A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| RU2015121799A (ru) * | 2012-11-09 | 2017-01-10 | Эвоник Корпорейшн | Способы сушки для регулировки свойств микрочастиц |
| WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
| SG11201604805XA (en) | 2013-12-16 | 2016-07-28 | Massachusetts Inst Technology | Fortified micronutrient salt formulations |
| WO2015095230A1 (en) * | 2013-12-16 | 2015-06-25 | Massachusetts Institute Of Technology | Micromolded or 3-d printed pulsatile release vaccine formulations |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| WO2015109180A2 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| TWI687428B (zh) | 2014-03-27 | 2020-03-11 | 中央研究院 | 反應性標記化合物及其用途 |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| JP7062361B2 (ja) | 2014-05-27 | 2022-05-06 | アカデミア シニカ | 抗ｈｅｒ２糖操作抗体群およびその使用 |
| CN106573971A (zh) | 2014-05-27 | 2017-04-19 | 中央研究院 | 抗cd20醣抗体及其用途 |
| JP7093612B2 (ja) | 2014-05-27 | 2022-06-30 | アカデミア シニカ | Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法 |
| JP7063538B2 (ja) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | 抗ＴＮＦα糖操作抗体群およびその使用 |
| US9439864B2 (en) * | 2014-07-07 | 2016-09-13 | Antriabio, Inc. | Solvent extraction from biodegradable microparticles |
| AU2015315294B2 (en) | 2014-09-08 | 2020-09-17 | Academia Sinica | Human iNKT cell activation using glycolipids |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| TWI736523B (zh) | 2015-01-24 | 2021-08-21 | 中央研究院 | 新穎聚醣結合物及其使用方法 |
| KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
| JP2019515876A (ja) | 2016-03-08 | 2019-06-13 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Ｎ−グリカンおよびそのアレイのモジュール合成のための方法 |
| WO2017172990A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| IL262296B1 (en) | 2016-04-22 | 2024-05-01 | Obi Pharma Inc | Cancer immunotherapy using immune activation or immune modulation by Globo-series antigens |
| MA45738A (fr) | 2016-07-13 | 2019-05-22 | Harvard College | Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser |
| KR20230117482A (ko) | 2016-07-27 | 2023-08-08 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| EP3491026A4 (de) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren |
| US10538592B2 (en) | 2016-08-22 | 2020-01-21 | Cho Pharma, Inc. | Antibodies, binding fragments, and methods of use |
| AU2017361549B2 (en) | 2016-11-21 | 2023-12-21 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| EP3791873A1 (de) | 2019-09-16 | 2021-03-17 | Universite De Bordeaux | Verfahren zur behandlung und/oder vorbeugung von erkrankungen und symptomen im zusammenhang mit bkca- und/oder sk-kanalophathien |
| AU2022226584A1 (en) | 2021-02-24 | 2023-08-17 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| ATE151638T1 (de) * | 1987-02-20 | 1997-05-15 | Genentech Inc | Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern |
| US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
| JP2653255B2 (ja) * | 1990-02-13 | 1997-09-17 | 武田薬品工業株式会社 | 長期徐放型マイクロカプセル |
-
1994
- 1994-10-13 WO PCT/US1994/011753 patent/WO1995011010A1/en active IP Right Grant
- 1994-10-13 DK DK94930794T patent/DK0724432T3/da active
- 1994-10-13 ES ES94930794T patent/ES2184769T3/es not_active Expired - Lifetime
- 1994-10-13 JP JP7512118A patent/JPH09504027A/ja not_active Withdrawn
- 1994-10-13 DE DE69431404T patent/DE69431404T2/de not_active Expired - Lifetime
- 1994-10-13 AT AT94930794T patent/ATE224184T1/de active
- 1994-10-13 EP EP94930794A patent/EP0724432B1/de not_active Expired - Lifetime
- 1994-10-13 CA CA2172509A patent/CA2172509C/en not_active Expired - Lifetime
- 1994-10-13 AU AU79807/94A patent/AU7980794A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0724432B1 (de) | 2002-09-18 |
| DE69431404D1 (de) | 2002-10-24 |
| EP0724432A1 (de) | 1996-08-07 |
| DE69431404T2 (de) | 2003-04-30 |
| CA2172509C (en) | 2010-08-24 |
| ES2184769T3 (es) | 2003-04-16 |
| CA2172509A1 (en) | 1995-04-27 |
| WO1995011010A1 (en) | 1995-04-27 |
| AU7980794A (en) | 1995-05-08 |
| DK0724432T3 (da) | 2003-01-27 |
| JPH09504027A (ja) | 1997-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE224184T1 (de) | Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe | |
| ATE223702T1 (de) | Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien | |
| DE3768833D1 (de) | Verfahren zur herstellung von hcmv-glykoproteinen, antikoerper dagegen und hcmv-vakzine und dazu zu verwendende rekombinante vektoren. | |
| ATE466869T1 (de) | Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden | |
| BR9809656A (pt) | Composição imunopotencializante | |
| DK1042001T3 (da) | Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner | |
| DE69231837T8 (de) | Antigen praesentierende ms2-huelle | |
| NO933126L (no) | Löselige ligander for CD40 | |
| DE60004496D1 (de) | Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff | |
| ATE249840T1 (de) | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung | |
| DK0851927T3 (da) | Forbindelser til immunterapi og diagnosticering af tuberkulose | |
| ATE198621T1 (de) | Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28 | |
| DE69800716D1 (de) | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen | |
| DK0885244T4 (da) | Peptidimmunogener til vaccination imod og til behandling af allergi | |
| DK0668772T3 (da) | Specifik immunsystemmodulering | |
| DE68907708D1 (de) | Verfahren zur probennahme von festen materialien und probenahmesystem zur durchfuehrung des verfahrens. | |
| ATE101876T1 (de) | Verfahren zur verringerung der heterogenitaet von monoklonalen antikoerpern. | |
| ATE416787T1 (de) | Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien | |
| DE58907880D1 (de) | Verfahren zur Herstellung aminierter Diketodi(het)aryl-pyrrolopyrrole und Verwendung derselben als photoleitfähige Substanzen. | |
| EP1079854A4 (de) | Zusammensetzungen und verfahren zur modulation einer immunantwort auf ein antigen | |
| ATE72400T1 (de) | Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen. | |
| DK0728015T3 (da) | Kombinatoriske polypeptidantigener | |
| DK192890A (da) | 24r-scumnol, fremgangsmaade til fremstilling heraf samt anvendelse af samme | |
| ATE95422T1 (de) | Ein synthetisches nonapeptid zur verwendung als adjuvant. | |
| ITRM910385A0 (it) | Vaccini utilizzanti eritrociti come veicoli di antigeni. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |